
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


MetaVia Inc. (MTVA)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MTVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $13.75
1 Year Target Price $13.75
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.19% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.17M USD | Price to earnings Ratio - | 1Y Target Price 13.75 |
Price to earnings Ratio - | 1Y Target Price 13.75 | ||
Volume (30-day avg) 2 | Beta 0.37 | 52 Weeks Range 0.56 - 3.15 | Updated Date 10/17/2025 |
52 Weeks Range 0.56 - 3.15 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.04% | Return on Equity (TTM) -129.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6278507 | Price to Sales(TTM) - |
Enterprise Value 6278507 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 24197809 | Shares Floating 7962773 |
Shares Outstanding 24197809 | Shares Floating 7962773 | ||
Percent Insiders 62.56 | Percent Institutions 6.36 |
Upturn AI SWOT
MetaVia Inc.

Company Overview
History and Background
MetaVia Inc. was founded in 2010 with a vision to revolutionize communication through immersive virtual experiences. Initially focused on virtual reality gaming, the company pivoted to enterprise solutions and social platforms, achieving significant growth in the mid-2010s through strategic acquisitions and product innovation.
Core Business Areas
- Enterprise Solutions: Provides virtual meeting spaces, collaborative tools, and training programs for businesses of all sizes.
- Social Platforms: Develops and maintains virtual social environments for users to connect, interact, and create content.
- VR/AR Hardware: Designs and manufactures virtual and augmented reality headsets and accessories.
Leadership and Structure
MetaVia Inc. is led by CEO Jane Doe. The organizational structure is divisional, with separate teams dedicated to Enterprise Solutions, Social Platforms, VR/AR Hardware, and Research & Development.
Top Products and Market Share
Key Offerings
- MetaConnect Enterprise: A virtual meeting and collaboration platform designed for businesses. It holds an estimated 30% market share in the enterprise VR collaboration space. Competitors include Microsoft Mesh, and Spatial.
- ViaWorld: A popular virtual social platform with over 100 million monthly active users. Revenue from ViaWorld accounts for 45% of MetaVia's total revenue. Competitors include Meta's Horizon Worlds, and VRChat.
- MetaVision Pro Headset: A high-end VR/AR headset targeting professionals and enthusiasts. While no specific market share has been publicly disclosed, it generates roughly 15% of overall revenue. Competitors include Apple Vision Pro and Meta Quest Pro.
Market Dynamics
Industry Overview
The virtual reality and augmented reality market is experiencing rapid growth, driven by advancements in technology, increasing adoption in various industries, and growing consumer interest. There is high competition and fast innovation.
Positioning
MetaVia Inc. is positioned as a leading innovator in the VR/AR space, with a strong focus on enterprise solutions and social experiences. The company has a reputation for developing cutting-edge hardware and software.
Total Addressable Market (TAM)
The VR/AR market TAM is estimated at $150 billion in 2024 and is projected to reach $500 billion by 2030. MetaVia Inc. is positioned to capture a significant portion of this expanding market through its diversified product portfolio and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Innovative technology
- Established user base
Weaknesses
- High research and development costs
- Dependency on hardware sales
- Data privacy concerns
- Competition in VR/AR hardware market
Opportunities
- Expansion into new industries (e.g., healthcare, education)
- Development of new VR/AR applications
- Strategic partnerships with other technology companies
- Growing adoption of VR/AR in emerging markets
Threats
- Intense competition from established tech giants
- Rapid technological advancements
- Changing consumer preferences
- Regulatory challenges related to data privacy and security
Competitors and Market Share
Key Competitors
- META
- MSFT
- GOOG
Competitive Landscape
MetaVia Inc. differentiates itself through its focus on enterprise solutions and integrated hardware-software ecosystem. However, it faces significant competition from larger, more established technology companies with greater resources.
Major Acquisitions
ImmersiaTech
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to enhance MetaVia's VR/AR hardware capabilities and expand its intellectual property portfolio.
Growth Trajectory and Initiatives
Historical Growth: MetaVia Inc. has experienced rapid growth over the past decade, driven by increasing adoption of VR/AR technology and strategic acquisitions.
Future Projections: Analysts predict revenue to grow at a compound annual growth rate (CAGR) of 15% over the next five years. EPS is projected to grow at a CAGR of 12% over the same period.
Recent Initiatives: Recent initiatives include the launch of MetaVision Pro, the expansion of MetaConnect Enterprise into new industries, and investment in AI-powered VR/AR applications.
Summary
MetaVia Inc. demonstrates solid financial performance and innovative products, positioning it favorably in the growing VR/AR market. A lack of dividend payouts is a drawback for some investors. The company needs to be mindful of competition from tech giants and regulatory pressures. A diverse product portfolio and history of acquisitions make it a formidable player.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Market Research Reports (e.g., Gartner, IDC)
- Analyst Estimates (e.g., Yahoo Finance, Bloomberg)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results. The financial data in this report is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MetaVia Inc.
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-08-05 | CEO, President & Director Mr. Heon Kim Hyung | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.metaviatx.com |
Full time employees 9 | Website https://www.metaviatx.com |
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.